Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a report published on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Bradmer Pharmaceuticals’ FY2024 earnings at $2.74 EPS and FY2025 earnings at $3.35 EPS.
Bradmer Pharmaceuticals Price Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- What is the Euro STOXX 50 Index?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
